All filters
Abstracts
Exploring Molecular Characteristics and Evolutionary Dynamics of the HIV-1 Epidemic in Montenegro Through Phylogenetic Analyses
S. Dragas
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Prevalence and spatiotemporal dynamics of the HIV-1 circulating recombinant form 03_AB (CRF03_AB) in the former Soviet Union
E. Ozhmegova
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Cabotegravir + Rilpivirine Every 2 Months Is Noninferior to Monthly: ATLAS-2M Study
P. Benn
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Short- and long-term direct medical costs of late and very late HIV presentation
L. Versteegh
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Treatment outcome among people living with HIV starting first-line rapid or GRT guided ART from 2015 to 2018
A. De Vito
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Evaluation of HIV-1 tropism in multidrug-resistant cART failing patients
Y. Bouba
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
DTG+3TC vs DTG+TDF/FTC (GEMINI1&2): Confirmed Virologic Withdrawals Through Week 96
J. van Wyk
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Emergence of Resistance in HIV-1 Integrase following Dolutegravir Treatment in Participants Aged 4 Weeks to <18 Years: Results from the IMPAACT P1093 Study
C. Vavro
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Assessment of Genotypic Patterns Associated with HIV-1 Sensitivity to Ibalizumab
H. Jullien
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
In vitro activity of Islatravir against HIV-1 mutants harboring multiple NRTI resistance mutations
F. Giammarino
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Detection in HIV proviral DNA of drug resistance mutations in patients with low permanent viral loads
P. Ferrer
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
HIV-DNA decay in ART-naïve patients starting a DTG-based dual vs triple therapy
F. Lombardi
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Role of analytical treatment interruption on HIV peripheral reservoir diversification
C. Alteri
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Similar levels of HIV-DNA and residual viremia are found in virologically suppressed individuals who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to EVG/COBI/FTC enrolled in the Be-OnE Study
M. Santoro
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Comprehensive assessment of SARS-CoV-2 key genetic elements single or in clusters underlying geographically-dependent genetic evolutionary adaptation and their impact on drugs binding affinity and immune escape
M. Alkhatib
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Case report: poor adherence to dolutegravir is associated with selection of resistance mutations T66I, G118R, E138A and L74I
M. Pauskar
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Integrase Resistance development after long-term suppressive treatment with Abacavir, Lamivudine and Dolutegravir
M. Obermeier
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Difficulty in reaching virological suppression in a long-term treated HIV-1 patient: rather the role of the reservoir than drug resistance?
E. Alidjinou
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Assessment of quality of life among patients with hepatitis C in Georgia
T. Abzianidze
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
HIV Seronegativity After Rapid ART: A Case Demonstrating Future Challenges in HIV Confirmation Testing in the Era of iART
K. Yan
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Multicentric Castleman Disease HHV-8 related in a HIV patient
A. Gjataj
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Variability in HIV Proviral DNA Genotyping Results from a Single Blood Draw
K. White
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Virological efficacy and resistance evaluation in people living with HIV starting an STR regimen
G. Stella
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020
Abstracts
Resistant minority variants observed in failing patients at week 48 in ANRS 170 QUATUOR trial (a 4/7 days maintenance strategy vs a 7/7 days regimen in patients with controlled viral load)
S. Lambert-Niclot
Reviews in Antiviral Therapy & Infectious Diseases 7, 2020
Presented at:
European Meeting on HIV & Hepatitis 2020